Merck Announces Phase 3 KEYNOTE‑B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum‑Resistant Recurrent Ovarian Cancer
The Phase‑3 KEYNOTE‑B96 trial met its key secondary endpoint of overall survival in all patients with platinum‑resistant recurrent ovarian cancer.
KEYNOTE‑B96, a randomized, double‑blind Phase‑3 trial combining pembrolizumab with paclitaxel (± bevacizumab), demonstrated a statistically significant overall survival benefit versus placebo plus the same chemotherapy backbone in all patients with platinum‑resistant recurrent ovarian cancer, including those with PD‑L1 expressing tumors.
Improved overall survival provides the first evidence that an immune‑checkpoint inhibitor‑based regimen can extend life for patients with platinum‑resistant recurrent ovarian cancer, a disease with historically poor outcomes and limited treatment options.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements